Stability Indicating RP-HPLC Method Development and Validation for Simultaneous Estimation of Dapagliflozin Propanediol Monohydrate and Eplerenone in Its Synthetic Mixture

The growing need for effective analytical techniques for combination drug therapy has led to the development of reliable and stability-indicating methods for quantitative estimation. The present work was aimed at developing and validating a reverse phase high performance liquid chromatographic (RP-HPLC) method for the simultaneous estimation of dapagliflozin propanediol monohydrate and eplerenone in a synthetic mixture. The chromatographic separation was achieved using a Cosmosil C18 column (250 mm × 4.6 mm, 5 µm) with a mobile phase consisting of phosphate buffer and methanol in the ratio of 30:70 % v/v. The detection was carried out at 228 nm. The retention times of dapagliflozin propanediol monohydrate and eplerenone were found to be 6.2 min and 2.6 min, respectively, indicating satisfactory separation of both analytes. The developed method was validated as per ICH guidelines for various parameters such as linearity, accuracy, precision, specificity, robustness, and system suitability. The method showed good linearity with correlation coefficients close to unity for both drugs. The accuracy of the method was confirmed by recovery studies, and precision studies showed %RSD values within acceptable limit indicating reproducibility. The specificity of the method was established by the absence of interference from excipients and degradation products. Forced degradation studies were performed under acidic, alkaline, oxidative, thermal, and photolytic conditions, and the results confirmed that the method is capable of effectively separating degradation products from the analytes, thereby demonstrating its stability-indicating nature. The developed RP-HPLC method was found to be simple, precise, accurate, and robust, making it suitable for routine quality control analysis and stability studies of dapagliflozin propanediol monohydrate and eplerenone in synthetic mixtures.

Dapagliflozin Propanediol Monohydrate, Eplerenone

1. Olokoba, A. B., Obateru, O. A., & Olokoba, L. B. (2012). Type 2 diabetes mellitus: A review of current trends. Oman Medical Journal, 27(4), 269–273. [Google Scholar] [Crossref]

2. Provenzano, M., Puchades, M. J., Garofalo, C., Jongs, N., D’Marco, L., Andreucci, M., De Nicola, L., & Gorriz, J. L. (2022). Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: A randomized crossover clinical trial. Journal of the American Society of Nephrology, 33(8), 1569–1580. [Google Scholar] [Crossref]

3. Soulié, M., Stephan, Y., Durand, M., Lima-Posada, I., Palacios-Ramírez, R., Nicol, L., Lopez-Andres, N., Mulder, P., & Jaisser, F. (2024). Benefit of combination therapy with dapagliflozin and eplerenone on cardiac function and fibrosis in rats with non-diabetic chronic kidney disease. Scientific Reports, 14(1), 23955. [Google Scholar] [Crossref]

4. CDSCO. (2024). FDC of dapagliflozin and eplerenone. Retrieved August 28, 2025. [Google Scholar] [Crossref]

5. Rajamahanti, S. G. (2017). Analytical method development and validation of a few drugs by RP-HPLC in pharmaceutical dosage forms (PhD thesis). Andhra University. [Google Scholar] [Crossref]

6. Braun, R. D. (2012). Introduction to instrumental analysis (2nd ed.). PharmaMed Press/BSP Books. [Google Scholar] [Crossref]

7. Bose, A. (2014). HPLC calibration process parameters in terms of system suitability test. Austin Chromatography, 1(2), 1–4. [Google Scholar] [Crossref]

8. Patil, P. S., & Kavita, D. (2022). High-performance liquid chromatography (HPLC) method development and validation. International Journal of Pharmaceutical Sciences Review and Research, 74(2), 23–29. [Google Scholar] [Crossref]

9. International Council for Harmonisation (ICH). (2022). Validation of analytical procedures: Text and methodology Q2(R2). [Google Scholar] [Crossref]

10. Vidushi, Y., Meenakshi, B., & Bharkatiya, M. (2017). A review on HPLC method development and validation. Research Journal of Life Sciences, Bioinformatics, Pharmaceutical and Chemical Sciences, 2(6), 166–178. [Google Scholar] [Crossref]

11. DrugBank. (2025). Dapagliflozin propanediol monohydrate. [Google Scholar] [Crossref]

12. DrugBank. (2025). Eplerenone. [Google Scholar] [Crossref]

13. PubChem. (2025). Eplerenone. [Google Scholar] [Crossref]

14. United States Pharmacopeia. (2024). United States pharmacopeia and national formulary (pp. 1364–1365). [Google Scholar] [Crossref]

15. Mante, G. V., Gupta, K. R., & Hemke, A. T. (2017). Estimation of dapagliflozin from its tablet formulation by UV-spectrophotometry. Pharmaceutical Methods, 8(2), 102–107. [Google Scholar] [Crossref]

16. Vadla, S., Putta, V., Nadipudi, S., Bilakanti, S., & Kudumula, N. (2023). Estimation method for dapagliflozin in bulk and marketed dosage form. International Journal of Pharmaceutical and Phytopharmacological Research, 13(4), 1–6. [Google Scholar] [Crossref]

17. Debata, J., Kumar, S., Jha, S. K., & Khan, A. (2017). A new RP-HPLC method development and validation of dapagliflozin. International Journal of Drug Development and Research, 9(2), 48–51. [Google Scholar] [Crossref]

18. Mante, G. V., Hemke, A. T., & Umekar, M. J. (2018). RP-HPLC method for estimation of dapagliflozin. International Journal of ChemTech Research, 11(1), 242–248. [Google Scholar] [Crossref]

19. Manoharan, G., Ismaiel, A. M., & Ahmed, Z. M. (2018). Stability-indicating RP-HPLC method development. Chemical Research Journal, 3(2), 159–164. [Google Scholar] [Crossref]

20. Verma, M. V., Patel, C. J., & Patel, M. M. (2017). Development and stability indicating HPLC method. International Journal of Applied Pharmaceutics, 9(5), 33–41. [Google Scholar] [Crossref]

21. Rao, B. R., Rao, V. V., & Venkateswarlu, B. S. (2019). RP-HPLC method for simultaneous estimation of dapagliflozin and saxagliptin in bulk samples. Journal of Pharmaceutical Sciences and Research, 11(1), 254–257. [Google Scholar] [Crossref]

22. Deepan, T., & Dhanaraju, M. D. (2018). Stability indicating HPLC method for the simultaneous determination of dapagliflozin and saxagliptin. Current Issues in Pharmacy and Medical Sciences, 31(1), 39–43. [Google Scholar] [Crossref]

23. Sharif, S., Bashir, R., Adnan, A., Mansoor, S., Ahmad, I., Ch, A. R., & Tahir, M. S. (2020). Stability indicating, pH and pKa dependent HPLC–DAD method for simultaneous determination of SGLT2 inhibitors. Chromatographia, 83(12), 1453–1465. [Google Scholar] [Crossref]

24. Siddique, W., Zulcaif, Umar, H., Usmani, S. J., Waqas, M., Gul, M., & Gul, M. (2025). Method development and validation of metformin HCl and dapagliflozin by RP-HPLC. Acta Chromatographica, 37(2), 176–182. [Google Scholar] [Crossref]

25. Kladi, E., Zerva, M., & Dotsikas, Y. (2024). A novel HPLC method for the simultaneous determination of empagliflozin and dapagliflozin. Archives of Pharmacy, 74(2), 267–280. [Google Scholar] [Crossref]

26. Prajapati, P., Rana, B., Pulusu, V. S., & Shah, S. (2024). Simultaneous chromatographic estimation of vildagliptin and dapagliflozin. Journal of AOAC International, 107(1), 212–222. [Google Scholar] [Crossref]

27. Indian Pharmacopoeia Commission. (2022). Indian pharmacopoeia (Vol. 2, pp. 2250–2251). Ghaziabad, India. [Google Scholar] [Crossref]

28. British Pharmacopoeia Commission. (2024). British pharmacopoeia. [Google Scholar] [Crossref]

29. Shailaja, B., Swarna, K., Afreen, M., & Kumar, A. (2015). A rapid assay method development and validation for estimation of eplerenone. International Journal of Pharmacy and Pharmaceutical Sciences, 7(9), 327–330. [Google Scholar] [Crossref]

30. Manasa, P., Jaffer, S. K., Ashwini, M., & Kumar, A. A. (2015). A simple UV assay method development for estimation of eplerenone. International Journal of Pharmacy and Pharmaceutical Sciences, 7(10), 348–351. [Google Scholar] [Crossref]

31. Rane, V. P., Patil, K. R., Sangshetti, J. N., Yeole, R. D., & Shinde, D. B. (2009). Stability-indicating RP-HPLC method for analysis of eplerenone. Acta Chromatographica, 21(4), 619–629. [Google Scholar] [Crossref]

32. Gide, P., Sonawane, S., & Chitnis, A. (2012). Development and validation of RP-HPLC method for estimation of eplerenone in spiked human plasma. Journal of Pharmaceutical Analysis, 2(5), 390–393. [Google Scholar] [Crossref]

33. Zhang, J. Y., Fast, D. M., & Breau, A. P. (2003). Development and validation of LC–MS/MS assay for eplerenone in plasma. Journal of Chromatography B, 787(2), 333–344. [Google Scholar] [Crossref]

34. Du, M., Pan, C., Chen, J., Song, M., Zhu, T., & Hang, T. (2016). Stability-indicating UPLC method for impurities in eplerenone. Journal of Separation Science, 39(15), 2907–2918. [Google Scholar] [Crossref]

35. Zhang, J. Y., Fast, D. M., & Breau, A. P. (2003). SPE–LC-MS/MS assay for eplerenone in human urine. Journal of Pharmaceutical and Biomedical Analysis, 31(1), 103–115. [Google Scholar] [Crossref]

36. Kumar, D. V., Srinivas, S., & Kumar, A. A. (2015). RP-HPLC method development and validation for estimation of eplerenone in tablets. International Journal of Pharmacy and Pharmaceutical Sciences, 360–364. [Google Scholar] [Crossref]

37. Sangshetti, J. N., Shinde, D., & Ma, B. A. (2009). Stability-indicating RP-HPLC method for eplerenone. Acta Chromatographica, 21(4), 619–629. [Google Scholar] [Crossref]

38. Sonawane, S., & Gide, P. (2011). Experimental design approach for forced degradation studies of eplerenone. Journal of Liquid Chromatography & Related Technologies, 34(17), 2020–2031. [Google Scholar] [Crossref]

39. Patel, K. S., Bendale, A., Luhar, S. V., & Narkhede, S. B. (2016). RP-HPLC method for simultaneous estimation of eplerenone and torsemide. Journal of Pharmaceutical Science and Bio-Scientific Research, 6(3), 283–290. [Google Scholar] [Crossref]

40. Hinge, M. A., & Patel, D. (2022). Optimization of HPLC method using central composite design. Brazilian Journal of Pharmaceutical Sciences, 58, e20219. [Google Scholar] [Crossref]

41. Thosar, S., Gokhale, R., & Tolbert, D. (2003). Immediate release eplerenone compositions (U.S. Patent No. 6,558,707). [Google Scholar] [Crossref]

42. Bian, Z. (2008). Eplerenone pharmaceutical composition (China Patent No. CN101152187A). [Google Scholar] [Crossref]

43. Shah, V., Redasani, V., & Ghongade, A. (2023). Pharmaceutical composition comprising dapagliflozin (U.S. Patent No. 11,660,308 B2). [Google Scholar] [Crossref]

44. Staric, R., & Berglez, S. (2019). Formulations containing amorphous dapagliflozin (U.S. Patent No. US20190175543A1). [Google Scholar] [Crossref]

45. Chivukula, K. R. (2020). Co-crystals of SGLT2 inhibitors and pharmaceutical compositions (U.S. Patent No. 10,738,038 B2). [Google Scholar] [Crossref]

46. Joshi, I., Jawarkar, S., & Sawale, A. (2022). Formulation and evaluation of pulsatile drug release tablets. International Journal of Creative Research Thoughts, 10(5), 872–885. [Google Scholar] [Crossref]

47. TCI Chemicals. (2026). Eplerenone. [Google Scholar] [Crossref]

48. Hinge, M., Patel, D., & Patel, A. (2019). Development and validation of UV spectrophotometric method for estimation of torsemide and eplerenone. International Journal of Pharmaceutical Sciences Review and Research, 56(2), 63–67. [Google Scholar] [Crossref]

49. Indian Pharmacopoeia Commission. (2022). Indian pharmacopoeia (Vol. 1, p. 618). Ghaziabad, India. [Google Scholar] [Crossref]

50. Kaczmarek, M., Przerada, S., Hrakovsky, J., & Dzik, J. (2022). Pharmaceutical composition comprising dapagliflozin (WO Patent No. WO2021165316A1). [Google Scholar] [Crossref]

• Development and Evaluation of Floating Alginate Beads of Esomeprazole
• Determination of pKa Value for Ranolazine and Atenolol Using UV Spectroscopy
• The Science of Sustained-Release Medications
• Development of Proteomics in Clinical Medicine
• Advances on Quinoline Derivatives: A Review of Synthesis and Biological Activities